WO2013163142A1 - Liquid pharmaceutical formulation containing ketorolac and tramadol - Google Patents

Liquid pharmaceutical formulation containing ketorolac and tramadol Download PDF

Info

Publication number
WO2013163142A1
WO2013163142A1 PCT/US2013/037737 US2013037737W WO2013163142A1 WO 2013163142 A1 WO2013163142 A1 WO 2013163142A1 US 2013037737 W US2013037737 W US 2013037737W WO 2013163142 A1 WO2013163142 A1 WO 2013163142A1
Authority
WO
WIPO (PCT)
Prior art keywords
pain
ketorolac
tramadol
liquid pharmaceutical
effective amount
Prior art date
Application number
PCT/US2013/037737
Other languages
French (fr)
Inventor
Wei-Zen Sun
Fangchen Lee
Chiung Ju Tsai
Yu-Hui Tsai
Hsiao-Chun Huang
Wen-Jen Lu
Shin Hong JANG
Original Assignee
Yung Shin Pharm. Ind. Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yung Shin Pharm. Ind. Co., Ltd. filed Critical Yung Shin Pharm. Ind. Co., Ltd.
Publication of WO2013163142A1 publication Critical patent/WO2013163142A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • This application relates to a liquid pharmaceutical formulation comprising ketorolac and tramadol.
  • This application also relates to the use of the pharmaceutical formulation in treating moderate to moderately severe pain such as postoperative pain (e.g., after cesarean delivery or other surgeries), cancer pain, visceral pain, and trauma pain.
  • moderate to moderately severe pain such as postoperative pain (e.g., after cesarean delivery or other surgeries), cancer pain, visceral pain, and trauma pain.
  • pain can be divided into three types: nociceptive, neuropathic, and mix-type.
  • Nociceptive pain is usually caused by noxious stimulation such as heat and cut that directly results in damage or injury to the body or tissue. Based on the initiation site of the pain, nociceptive pain can be further divided into two types: somatic and visceral pain. Somatic pain arises from bone, joint, muscle, skin, or connective tissues that directly in contact with the external noxious stimuli. Visceral pain arises from compression, extension, and injury of the internal organs. Most people describe the symptoms as achy, sharp, stinging, and throbbing. Nociceptive pain is usually short in duration and end when the damage recovers. Examples of nociceptive pain include postoperative pain, sprains, bone fractures, burns, bumps, bruises, and inflammatory pain (with the exception of inflammation caused by arthritis).
  • Neuropathic pain is originated from spontaneous ectopic neuron discharge in the nervous system either in central or in peripheral. Due to the underlying etiologies are usually irreversible, most of neuropathic pain are chronic pain. Most people describe neuropathic pain as shooting, burning, tingling, lancinating, electric shock qualities, numbness, and persistent allodynia. The nomenclature of neuropathic pain is based on the site of initiating nervous system with the etiology; for examples, central post-stroke pain, diabetes peripheral neuropathy, post-herpetic (or post-shingles) neuralgia, terminal cancer pain, phantom limb pain.
  • Mix-type pain is featured by the coexistence of both nociceptive and neuropathic pain.
  • muscle pain trigger central or peripheral neuron sensitization leading to chronic low back pain, migraine, and myofacial pain.
  • Clinically pain intensity is rated on a scale of 0 to 10; with 0 is no pain, 1-3 is mild pain, 4-6 is moderate pain, and 7-10 is severe pain. For example, 8-9 is designated for moderately severe pain.
  • WHO "3 -Step” Guideline provides the guideline for managing pain.
  • the “3 -Step” is determined by the pain intensity and the analgesia activity of drugs.
  • acetaminophen, NSAIDs, and opioids all have their inherent drawbacks. Acetaminophen and NSAIDs often exhibit ceiling effect (upper limit of pain relief). Once that upper limit is reached, taking additional medication provides no further pain relief.
  • NSAIDs has end organ toxicities in heart, liver, GI tract, and kidney at the regular doses. Opioids usually cause intolerable adverse effects such as constipation, respiratory depression, physical dependence and abuse problems. Primarily, NSAIDs provide peripheral anti-nociception and opioids provide central anti-nociception.
  • Ketorolac molecular weight 255.27
  • ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) in the family of heterocyclic acetic acid derivative, often used as an analgesic.
  • NSAID non-steroidal anti-inflammatory drug
  • Ketorolac acts by inhibiting the bodily synthesis of prostaglandins.
  • Ketorolac in its oral (tablet or capsule) and intramuscular (injected) preparations is a racemic mixture of both (S)-(-)-ketorolac, the active isomer, and (R)-(+)-ketorolac. This drug is administered to treat moderate pain or, combined with reduced opioid doses, for severe pain.
  • Tramadol (molecular weight 263.4), (lR,2R)-rel-2-[(dimethylamino)methyl]- l-(3- methoxyphenyl)cyclohexanol, is in a class of opiate agonists.
  • Tramadol is classified as a central nervous system drug usually marketed as the hydrochloride salt (tramadol hydrochloride).
  • Tramadol hydrochloride is a centrally acting weak opioid analgesic with no anti-inflammatory activity, used in treating moderate to severe pain. The drug has a wide range of applications, including treatment for restless leg syndrome and fibromyalgia.
  • the present invention is directed to a liquid pharmaceutical composition for treating a patient having moderate to severe pain.
  • the pharmaceutical composition comprises an effective amount of ketorolac or ketorolac tromethamine, and an effective amount of tramadol or its pharmaceutically acceptable salt, in a liquid formulation.
  • the effective amount of ketorolac or ketorolac tromethamine is 42-52.5 mg, and the effective amount of tramadol or its pharmaceutically acceptable salt is 28-35 mg.
  • the effective amount of ketorolac or ketorolac tromethamine is 21-26.25 mg, and the effective amount of tramadol or its pharmaceutically acceptable salt is 70-87.5 mg.
  • FIG. 1 is a scatter plot of visual analogue scale vs. time from first injection of the liquid pharmaceutical composition.
  • K60 Ketorolac 60 mg
  • K60+T40 Ketorolac 60 mg + tramadol 40 mg
  • K45+T75 Ketorolac 45 mg + tramadol 75 mg
  • K30+T100 Ketorolac 30 mg + tramadol 100 mg
  • T100 tramadol 100 mg.
  • the present invention is directed to a liquid pharmaceutical formulation comprising
  • ketorolac or ketorolac tromethamine collectively referred to as ketorolac in this application
  • tramadol or their pharmaceutically acceptable salt thereof collectively referred to as tramadol in this application
  • the liquid ketorolac- tramadol formulation is suitable for injection, for example, intravenous injection or intramuscular injection.
  • the liquid ketorolac -tramadol formulation is also suitable for oral administration.
  • the liquid ketorolac -tramadol formulation is stable for at least 1 day, preferably 3 days, more preferably 7 days at room temperature (about 22-28 °C). "Stable,” as used herein, refers that both drug maintains at least 80%, preferably 90%, of their initial amounts in the solution, and the solution does not show visible precipitation.
  • ketorolac -tramadol formulation provides combined benefits of the two individual drugs of ketorolac and tramadol.
  • the advantages of combined ketorolac -tramadol formulation include: (a) providing shorter analgesia onset and prolonged duration, (b) providing both central and peripheral analgesic effect by complementary mechanisms of actions, and (c) reducing the dose of each drug and thus minimizing side effects.
  • ketorolac- tramadol formulation is superior to one single drug, because the addition of tramadol eliminates the ceiling effect of ketorolac.
  • ketorolac-tramadol formulation can be used to treat pain with moderately severe intensity.
  • the liquid ketorolac -tramadol solution is preferably a clear solution, but it may also be a suspension form and emulsion form.
  • the effective dosage of the liquid ketorolac -tramadol formulation in general is about 7.5-60 mg of ketorolac and 10-100 mg of tramadol.
  • Effective amounts of ketorolac and tramadol may also be 42-59 mg of ketorolac and tramadol.
  • tramadol 14-71 mg of tramadol; preferably 42-52.5 mg of ketorolac, and 28-35 mg of tramadol; or 45- 52.5 mg of ketorolac, and 30-35 mg of tramadol.
  • Effective amounts of ketorolac and tramadol may also be 9-42 mg ketorolac and 71- 99 mg of tramadol; preferably 18.75-26.25 mg of ketorolac, and 62.5-87.5 mg of tramadol; or 21-26.25 mg of ketorolac, and 70-87.5 mg of tramadol.
  • the dosage is typically is formulated in 1-20 ml for intravenous injection and 0.5-2 ml for intramuscular injection.
  • concentration (mg/ml) of each drug in the pharmaceutical composition can be calculated by dividing the amount (mg) by the volume (ml).
  • the liquid pharmaceutical formulation contains ketorolac or ketorolac tromethamine and tramadol or its pharmaceutically acceptable salt in water, at pH 5.0-8.0, preferably pH 6- 8.
  • the liquid pharmaceutical formulation may contain saline.
  • the liquid pharmaceutical formulation may also contain a buffer to stabilize the pH.
  • the liquid pharmaceutical formulation may contain a pharmaceutically acceptable carrier, known to those skilled in the art.
  • known pharmaceutically acceptable carriers for injection form or for oral form can be added to the liquid pharmaceutical formulation.
  • the liquid pharmaceutical formulation preferably does not contain any other drug or any other active ingredient in addition to ketorolac and tramadol.
  • the liquid pharmaceutical formulation does not contain metoclopramide or MgS0 4 . Pharmaceutical Use of the Ketorolac-Tramadol Formulation
  • the ketorolac-tramadol formulation of the present invention is useful in the management of pain of moderate to moderately severe intensity (scale 4-9 or 6-9), preferably in the management of pain of moderately severe intensity (scale 8-9).
  • the ketorolac - tramadol formulation is particularly useful in the management of postoperative pain, cancer pain, visceral pain and trauma pain.
  • the present invention is directed to a method for treating a patient with moderate to moderately severe pain (pain scale 4-9, preferably 6-9, more preferably 8-9).
  • the method comprises: identifying a patient suffering from pain, and administering to said patient a liquid ketorolac -tramadol formulation, in an effective amount.
  • An effective amount refers to an amount that is effective to reduce or relief pain from a patient.
  • the present invention reduces pain score to ⁇ 5.3.
  • the effective amount of ketorolac or ketorolac tromethamine is 42-52.5 mg, and the effective amount of tramadol or its pharmaceutically acceptable salt is 28-35 mg.
  • the effective amount of ketorolac or ketorolac tromethamine is 45- 52.5 mg, and the effective amount of tramadol or its pharmaceutically acceptable salt is 30-35 mg.
  • the effective amount of ketorolac or ketorolac tromethamine is 18.75-26.25 mg, and the effective amount of tramadol or its pharmaceutically acceptable salt is 62.5-87.5 mg.
  • the effective amount of ketorolac or ketorolac tromethamine is 21-26.25 mg, and the effective amount of tramadol or its pharmaceutically acceptable salt is 70-87.5 mg.
  • the liquid ketorolac/tramadol formulation can be administered by intravenous injection, intramuscular injection, or oral administration.
  • the intravenous injection can be administered by bolus injection or continuous infusion; bolus of 1, 2, 3, or 4 times is preferred.
  • the total volume for intravenous injection is 1-20 ml, or 2-10 ml, and for intramuscular injection is ⁇ 2 ml, e.g., 0.5-1.5 ml.
  • the present method is useful in treating moderately severe pain with pain intensity of 8-9.
  • the method is also useful in treating postoperative pain, such as pain after Cesarean, postoperative pain after other surgeries, severe cancer pain, visceral pain, or trauma pain. Postoperative pains
  • Postoperative pain is resulted from the somatic pain and visceral pain.
  • the somatic pain arises from the direct noxious impulse at injury sites (cut).
  • Visceral pain arises from the compression, extension, or inflammation of internal organs.
  • the liquid ketorolac-tramadol formulation offers benefit to patients whose pain is caused from inflammation (COX1/C0X2) and visceral pain. It also enhances anti-nociceptive response from central by modulation of ⁇ receptor and the level of serotonin and noradrenalin
  • the liquid ketorolac -tramadol formulation is particularly effective in the management of postoperative pain after cesarean for the following reasons:
  • ketorolac by ketorolac offer better anti-inflammatory and analgesic effects than acetaminophen alone.
  • liquid ketorolac -tramadol formulation is useful in the pain control after other types of surgery, such as coronary artery bypass grafting (CABG), lumbar disc surgery, orthopaedia, and tonsillectomy.
  • CABG coronary artery bypass grafting
  • lumbar disc surgery lumbar disc surgery
  • orthopaedia orthopaedia
  • tonsillectomy a type of surgery
  • Postoperative pain is mostly acute and severe.
  • the management of postoperative pain usually starts at one hour after surgery and continue for another 48-72 hours. Since most patients are hospitalized after major surgeries, parenteral administration of analgesics is considered to be easy and convenient.
  • Parenteral administration of the liquid ketorolac- tramadol formulation offers benefit in the increase of drug exposure and shorter onset.
  • drug absorption can be variable in the first 24 hours following surgery.
  • the preferred route of administration for post-operative pain is intravenous injection or intramuscular injection.
  • Cancer pain is the result of tissue damage caused by the tumor, the effects of chemotherapy, radiation, or surgery. Cancer pain can occur at any stage of cancer. The pain intensity ranges from moderate to severe pain. Cancer patients at terminal phase often experience an intolerable severe pain, in which the highly potent opioids like morphine are commonly used.
  • Prostaglandins-induced inflammation and nociceptor sensitization contributes to a varying extent in the process of cancer and exacerbation of nociception.
  • Cancer pain can be nociceptive, neuropathic, or both depending on the course of cancer.
  • the liquid ketorolac- tramadol formulation offers benefit to the cancer patients whose pain results from severe inflammation (prostaglandin) and abnormal excitability of sodium channels. It also enhances anti-nociceptive response from central by modulation of ⁇ receptor and the level of serotonin and noradrenalin.
  • the liquid ketorolac -tramadol formulation is useful in the management of cancer pain for the following reasons:
  • Cancer pain is mainly both inflammatory and neuropathic.
  • the liquid ketorolac- tramadol formulation which offers both anti-inflammation and nerve block activity, is effective in the management of cancer pain with moderately severe intensity.
  • liquid ketorolac -tramadol formulation can be used in cancer patients at terminal stage for reducing the use of morphine in pain relief.
  • Terminal stage cancer patients with severe pain can be acute and chronic with occasional breakthrough pain with moderate to severe intensity.
  • parenteral administration by IM or IV provides rapid and effective pain relief.
  • the invention is illustrated further by the following examples that are not to be construed as limiting the invention in scope to the specific procedures described in them.
  • Ketorolac tromethamine (30 mg/ml, pH 6-8) was obtained from Yung Shin
  • Ketorolac tromethamine solutions were adjusted to different pH (pH 5, 6, 7, 8, and 9) with HCl or NaOH and stored at room temperature.
  • the solutions having different pH's were tested at day 0, 1, 3, and 7 to measure the contents of ketorolac tromethamine by HPLC.
  • ketorolac tromethamine (30 mg/ml) was stable for 7 days at room temperature at pH 5-9; the contents of ketorolac tromethamine were 98.4-101.7% after 7 days.
  • Tramadol 50 mg/ml, pH 6-8) was obtained from Grunenthal GMBH Products.
  • the tramadol solutions were adjusted to different pH (pH 5, 6, 7, 8, and 9) with HCl or NaOH and stored at room temperature.
  • the solutions having different pH's were tested at day 0, 1, 3, and 7 to measure the contents of tramadol by HPLC.
  • the results showed that tramadol was stable for 7 days at room temperature at pH 5-8; the contents of tramadol were 97.4-102.4% after 7 days.
  • tramadol precipitated out and had 70.4% of the initial amount remained in the solution at day 0, and had 56.4% of the initial amount remained in the solution after day 1, 3, 7, days.
  • Stability of Ketorolac and Tramadol 50 mg/ml, pH 6-8) was obtained from Grunenthal GMBH Products.
  • the tramadol solutions were adjusted to different pH (pH 5, 6, 7, 8, and 9) with HCl or NaOH
  • Ketorolac tromethamine (30 mg/ml) and tramadol (50 mg/ml) were mixed together with saline to provide a mixture solution containing ketorolac tromethamine (2 mg/ml) and Tramadol (20 mg/ml).
  • the mixture solutions were adjusted to different pH (pH 5, 6, 7, 8, and 9) with HC1 or NaOH and stored at room temperature. The mixture solutions were observed for its appearance at day 0, 1, 3, and 7.
  • the objective of this study is to test the safety profiles and efficacy for pre-mixed ketorolac and tramadol liquid formulation for treatment of post-operative pain.
  • Ketorolac tromethamine (Keto, 30 mg/ml) was obtained from Yung Shin
  • Tramadol hydrochloride 50 mg/ml was obtained from Grunenthal GMBH Products. The two drugs were pre-mixed together with saline to a total volume of 12.0 or 12.5 ml to provide 5 different concentrations as follows.
  • the initial dose (quarter of the maximum dose) of 2.5 ml was given by intravenous injection to each patient at time zero, and then doses of 2.5 ml were given by intravenous injection to the patient every 10 minutes, until the patient's pain score was ⁇ 5 or the dose is used up.
  • subjects rated their most severe pain score > 5 were randomized to one of the five groups of ketorolac and/or tramadol.
  • An initial dose of a quarter of volume (2.5 ml) treatment was given to patients, and subsequently 2.5 ml was given at about 10 minutes, 20 minutes, and 30 minutes, if subject's most severe pain level was still moderate to severe (pain score > 5).
  • the pain scores and vital signs were assessed every 5 minutes after each dose. If the subject rated the most severe pain score ⁇ 5 or the subject had received the maximum dose, then the subject stopped taking the liquid ketorolac and tramadol formulation and the subject was given direct access to a morphine PCA pump.
  • VAS Visual Analog Scale scoring system was used to assess the pain intensity (0- 10) by patient. 10 means the most severe pain and 0 means no pain. A horizontal line, 10 cm (100 mm) in length, was anchored by word descriptors, "No pain” and "Very severe pain", at each end. The VAS score was determined by measuring in millimeters from the left hand end of the line to the point that the subject marks. The study nurse measured the length from point 0 (no pain) to the mark and transcript to a number between 0.0 to 10.0 cm. The pain score at 0, 5, 10, 15, 20, 35, 30, 35, and 40 minutes of each patient were recorded.
  • the mean VAS score of each group at 0, 5, 10, 15, 20, 35, 30, 35, and 40 minutes was plotted vs. time from the initial injection and shown as FIG. 1.
  • patients treated with Group II reduced pain score to ⁇ 5 at about 28-35 minutes, or 30-35 minutes.
  • the accumulated dosages at 28-35 minutes are calculated to be ketorolac, 42-52.5 mg, and tramadol, 28-35 mg.
  • the accumulated dosages at 30-35 minutes are calculated to be ketorolac, 45-52.5 mg, and tramadol, 30-35 mg.
  • the accumulated dosages at 25-35 minutes are calculated to be ketorolac, 18.75-26.25 mg, and tramadol, 62.5-87.5 mg.
  • the accumulated dosages at 28-35 minutes are calculated to be ketorolac, 21-26.25 mg, and tramadol, 70-87.5 mg.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The prevent invention relates to a liquid pharmaceutical composition for treating a patient having moderate to severe pain. The liquid pharmaceutical composition comprises an effective amount of ketorolac or ketorolac tromethamine, and an effective amount of tramadol or its pharmaceutically acceptable salt. The liquid pharmaceutical composition is effective in reducing pain score from 8-9 to 5.3 or less.

Description

LIQUID PHARMACEUTICAL FORMULATION CONTAINING KETOROLAC AND TRAMADOL
TECHNICAL FIELD
This application relates to a liquid pharmaceutical formulation comprising ketorolac and tramadol. This application also relates to the use of the pharmaceutical formulation in treating moderate to moderately severe pain such as postoperative pain (e.g., after cesarean delivery or other surgeries), cancer pain, visceral pain, and trauma pain. BACKGROUND OF THE INVENTION
Based on the physical causes, pain can be divided into three types: nociceptive, neuropathic, and mix-type.
Nociceptive pain is usually caused by noxious stimulation such as heat and cut that directly results in damage or injury to the body or tissue. Based on the initiation site of the pain, nociceptive pain can be further divided into two types: somatic and visceral pain. Somatic pain arises from bone, joint, muscle, skin, or connective tissues that directly in contact with the external noxious stimuli. Visceral pain arises from compression, extension, and injury of the internal organs. Most people describe the symptoms as achy, sharp, stinging, and throbbing. Nociceptive pain is usually short in duration and end when the damage recovers. Examples of nociceptive pain include postoperative pain, sprains, bone fractures, burns, bumps, bruises, and inflammatory pain (with the exception of inflammation caused by arthritis).
Neuropathic pain is originated from spontaneous ectopic neuron discharge in the nervous system either in central or in peripheral. Due to the underlying etiologies are usually irreversible, most of neuropathic pain are chronic pain. Most people describe neuropathic pain as shooting, burning, tingling, lancinating, electric shock qualities, numbness, and persistent allodynia. The nomenclature of neuropathic pain is based on the site of initiating nervous system with the etiology; for examples, central post-stroke pain, diabetes peripheral neuropathy, post-herpetic (or post-shingles) neuralgia, terminal cancer pain, phantom limb pain.
Mix-type pain is featured by the coexistence of both nociceptive and neuropathic pain. For example, muscle pain trigger central or peripheral neuron sensitization leading to chronic low back pain, migraine, and myofacial pain. Clinically pain intensity is rated on a scale of 0 to 10; with 0 is no pain, 1-3 is mild pain, 4-6 is moderate pain, and 7-10 is severe pain. For example, 8-9 is designated for moderately severe pain.
WHO "3 -Step" Guideline provides the guideline for managing pain. The "3 -Step" is determined by the pain intensity and the analgesia activity of drugs.
(a) 1st Step mild pain: Acetaminophen, NSAIDs, or combination of both. Common used NSAIDs including aspirin, diclofenac, indomethacin, sulindac, ketoprofen, etodolac, ketorolac.
(b) 2nd Step moderate pain: NSAIDs plus opiate, including aspirin or acetaminophen with codein, oxycodon, dihydrocodein, hydrocodon, tramadol
(c) 3rd Step severe pain: Strong opiate including morphine, hydromorphine, methadol, levorphanol, fentanyl, oxycodon
It is well recognized that acetaminophen, NSAIDs, and opioids all have their inherent drawbacks. Acetaminophen and NSAIDs often exhibit ceiling effect (upper limit of pain relief). Once that upper limit is reached, taking additional medication provides no further pain relief. In addition, NSAIDs has end organ toxicities in heart, liver, GI tract, and kidney at the regular doses. Opioids usually cause intolerable adverse effects such as constipation, respiratory depression, physical dependence and abuse problems. Primarily, NSAIDs provide peripheral anti-nociception and opioids provide central anti-nociception.
Ketorolac (molecular weight 255.27), or ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) in the family of heterocyclic acetic acid derivative, often used as an analgesic. Ketorolac acts by inhibiting the bodily synthesis of prostaglandins. Ketorolac in its oral (tablet or capsule) and intramuscular (injected) preparations is a racemic mixture of both (S)-(-)-ketorolac, the active isomer, and (R)-(+)-ketorolac. This drug is administered to treat moderate pain or, combined with reduced opioid doses, for severe pain.
Tramadol (molecular weight 263.4), (lR,2R)-rel-2-[(dimethylamino)methyl]- l-(3- methoxyphenyl)cyclohexanol, is in a class of opiate agonists. Tramadol is classified as a central nervous system drug usually marketed as the hydrochloride salt (tramadol hydrochloride). Tramadol hydrochloride is a centrally acting weak opioid analgesic with no anti-inflammatory activity, used in treating moderate to severe pain. The drug has a wide range of applications, including treatment for restless leg syndrome and fibromyalgia. SUMMARY OF THE INVENTION
The present invention is directed to a liquid pharmaceutical composition for treating a patient having moderate to severe pain. The pharmaceutical composition comprises an effective amount of ketorolac or ketorolac tromethamine, and an effective amount of tramadol or its pharmaceutically acceptable salt, in a liquid formulation.
In one embodiment, the effective amount of ketorolac or ketorolac tromethamine is 42-52.5 mg, and the effective amount of tramadol or its pharmaceutically acceptable salt is 28-35 mg.
In another embodiment, the effective amount of ketorolac or ketorolac tromethamine is 21-26.25 mg, and the effective amount of tramadol or its pharmaceutically acceptable salt is 70-87.5 mg.
BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 is a scatter plot of visual analogue scale vs. time from first injection of the liquid pharmaceutical composition. K60= Ketorolac 60 mg, K60+T40= Ketorolac 60 mg + tramadol 40 mg, K45+T75= Ketorolac 45 mg + tramadol 75 mg, K30+T100= Ketorolac 30 mg + tramadol 100 mg, T100= tramadol 100 mg.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to a liquid pharmaceutical formulation comprising
(a) ketorolac or ketorolac tromethamine (collectively referred to as ketorolac in this application) and (b) tramadol or their pharmaceutically acceptable salt thereof (collectively referred to as tramadol in this application), in an aqueous solution. The liquid ketorolac- tramadol formulation is suitable for injection, for example, intravenous injection or intramuscular injection. The liquid ketorolac -tramadol formulation is also suitable for oral administration. The liquid ketorolac -tramadol formulation is stable for at least 1 day, preferably 3 days, more preferably 7 days at room temperature (about 22-28 °C). "Stable," as used herein, refers that both drug maintains at least 80%, preferably 90%, of their initial amounts in the solution, and the solution does not show visible precipitation.
The liquid ketorolac -tramadol formulation provides combined benefits of the two individual drugs of ketorolac and tramadol. The advantages of combined ketorolac -tramadol formulation include: (a) providing shorter analgesia onset and prolonged duration, (b) providing both central and peripheral analgesic effect by complementary mechanisms of actions, and (c) reducing the dose of each drug and thus minimizing side effects. Further, since NSAIDs can only manage mild to moderate pain due to a ceiling effect, ketorolac- tramadol formulation is superior to one single drug, because the addition of tramadol eliminates the ceiling effect of ketorolac. Thus, ketorolac-tramadol formulation can be used to treat pain with moderately severe intensity. These improvements offer more treatment options to patients.
The liquid ketorolac -tramadol solution is preferably a clear solution, but it may also be a suspension form and emulsion form.
The effective dosage of the liquid ketorolac -tramadol formulation in general is about 7.5-60 mg of ketorolac and 10-100 mg of tramadol.
Effective amounts of ketorolac and tramadol may also be 42-59 mg of ketorolac and
14-71 mg of tramadol; preferably 42-52.5 mg of ketorolac, and 28-35 mg of tramadol; or 45- 52.5 mg of ketorolac, and 30-35 mg of tramadol.
Effective amounts of ketorolac and tramadol may also be 9-42 mg ketorolac and 71- 99 mg of tramadol; preferably 18.75-26.25 mg of ketorolac, and 62.5-87.5 mg of tramadol; or 21-26.25 mg of ketorolac, and 70-87.5 mg of tramadol.
The dosage is typically is formulated in 1-20 ml for intravenous injection and 0.5-2 ml for intramuscular injection. The concentration (mg/ml) of each drug in the pharmaceutical composition can be calculated by dividing the amount (mg) by the volume (ml).
The liquid pharmaceutical formulation contains ketorolac or ketorolac tromethamine and tramadol or its pharmaceutically acceptable salt in water, at pH 5.0-8.0, preferably pH 6- 8. The liquid pharmaceutical formulation may contain saline. The liquid pharmaceutical formulation may also contain a buffer to stabilize the pH. The liquid pharmaceutical formulation may contain a pharmaceutically acceptable carrier, known to those skilled in the art. For example, known pharmaceutically acceptable carriers for injection form or for oral form can be added to the liquid pharmaceutical formulation. The liquid pharmaceutical formulation preferably does not contain any other drug or any other active ingredient in addition to ketorolac and tramadol. For example, the liquid pharmaceutical formulation does not contain metoclopramide or MgS04. Pharmaceutical Use of the Ketorolac-Tramadol Formulation
Based on the known analgesic-related mechanism of actions and reported clinical potentials, the ketorolac-tramadol formulation of the present invention is useful in the management of pain of moderate to moderately severe intensity (scale 4-9 or 6-9), preferably in the management of pain of moderately severe intensity (scale 8-9). The ketorolac - tramadol formulation is particularly useful in the management of postoperative pain, cancer pain, visceral pain and trauma pain.
The present invention is directed to a method for treating a patient with moderate to moderately severe pain (pain scale 4-9, preferably 6-9, more preferably 8-9). The method comprises: identifying a patient suffering from pain, and administering to said patient a liquid ketorolac -tramadol formulation, in an effective amount. "An effective amount," as used herein, refers to an amount that is effective to reduce or relief pain from a patient. The present invention reduces pain score to < 5.3.
In one embodiment, the effective amount of ketorolac or ketorolac tromethamine is 42-52.5 mg, and the effective amount of tramadol or its pharmaceutically acceptable salt is 28-35 mg. Preferably, the effective amount of ketorolac or ketorolac tromethamine is 45- 52.5 mg, and the effective amount of tramadol or its pharmaceutically acceptable salt is 30-35 mg.
In another embodiment, the effective amount of ketorolac or ketorolac tromethamine is 18.75-26.25 mg, and the effective amount of tramadol or its pharmaceutically acceptable salt is 62.5-87.5 mg. Preferably, the effective amount of ketorolac or ketorolac tromethamine is 21-26.25 mg, and the effective amount of tramadol or its pharmaceutically acceptable salt is 70-87.5 mg.
The liquid ketorolac/tramadol formulation can be administered by intravenous injection, intramuscular injection, or oral administration.
The intravenous injection can be administered by bolus injection or continuous infusion; bolus of 1, 2, 3, or 4 times is preferred. In general, the total volume for intravenous injection is 1-20 ml, or 2-10 ml, and for intramuscular injection is < 2 ml, e.g., 0.5-1.5 ml.
The present method is useful in treating moderately severe pain with pain intensity of 8-9. The method is also useful in treating postoperative pain, such as pain after Cesarean, postoperative pain after other surgeries, severe cancer pain, visceral pain, or trauma pain. Postoperative pains
Postoperative pain is resulted from the somatic pain and visceral pain. The somatic pain arises from the direct noxious impulse at injury sites (cut). The sensitization of afferent fibers at injury sites driving central sensitization. Visceral pain arises from the compression, extension, or inflammation of internal organs. The liquid ketorolac-tramadol formulation offers benefit to patients whose pain is caused from inflammation (COX1/C0X2) and visceral pain. It also enhances anti-nociceptive response from central by modulation of μ receptor and the level of serotonin and noradrenalin The liquid ketorolac -tramadol formulation is particularly effective in the management of postoperative pain after cesarean for the following reasons:
(a) Visceral pain caused by uterus contraction is the main component of pain after cesarean delivery. Ketorolac is highly effective in relief visceral pain.
(b) Prostaglandin involves in both tissue injury and uterus contraction. Inhibition of
PGE2 by ketorolac offer better anti-inflammatory and analgesic effects than acetaminophen alone.
(c) The mechanisms of action of the liquid ketorolac -tramadol formulation responsible for Cesarean pain relief include inhibition on COX1 and COX2, sodium current, serotonin and noradrenaline reuptake and activation of g receptor.
Over half of the postoperative pain patients still experience inadequate pain relief with currently available treatment. The liquid ketorolac -tramadol formulation is useful in the pain control after other types of surgery, such as coronary artery bypass grafting (CABG), lumbar disc surgery, orthopaedia, and tonsillectomy.
Postoperative pain is mostly acute and severe. The management of postoperative pain usually starts at one hour after surgery and continue for another 48-72 hours. Since most patients are hospitalized after major surgeries, parenteral administration of analgesics is considered to be easy and convenient. Parenteral administration of the liquid ketorolac- tramadol formulation offers benefit in the increase of drug exposure and shorter onset. In addition, drug absorption can be variable in the first 24 hours following surgery. The preferred route of administration for post-operative pain is intravenous injection or intramuscular injection.
Cancer Pain
Cancer pain is the result of tissue damage caused by the tumor, the effects of chemotherapy, radiation, or surgery. Cancer pain can occur at any stage of cancer. The pain intensity ranges from moderate to severe pain. Cancer patients at terminal phase often experience an intolerable severe pain, in which the highly potent opioids like morphine are commonly used.
Prostaglandins-induced inflammation and nociceptor sensitization contributes to a varying extent in the process of cancer and exacerbation of nociception. Cancer pain can be nociceptive, neuropathic, or both depending on the course of cancer. The liquid ketorolac- tramadol formulation offers benefit to the cancer patients whose pain results from severe inflammation (prostaglandin) and abnormal excitability of sodium channels. It also enhances anti-nociceptive response from central by modulation of μ receptor and the level of serotonin and noradrenalin.
The liquid ketorolac -tramadol formulation is useful in the management of cancer pain for the following reasons:
(a) Cancer pain is mainly both inflammatory and neuropathic. The liquid ketorolac- tramadol formulation, which offers both anti-inflammation and nerve block activity, is effective in the management of cancer pain with moderately severe intensity.
(b) The liquid ketorolac -tramadol formulation can be used in cancer patients at terminal stage for reducing the use of morphine in pain relief.
Terminal stage cancer patients with severe pain can be acute and chronic with occasional breakthrough pain with moderate to severe intensity. For the management of acute and breakthrough pain, parenteral administration by IM or IV provides rapid and effective pain relief. The invention is illustrated further by the following examples that are not to be construed as limiting the invention in scope to the specific procedures described in them.
EXAMPLES
Example 1. Compatibility Experiment
a. Stability of Ketorolac tromethamine
Ketorolac tromethamine (30 mg/ml, pH 6-8) was obtained from Yung Shin
Pharmaceuticals. The Ketorolac tromethamine solutions were adjusted to different pH (pH 5, 6, 7, 8, and 9) with HCl or NaOH and stored at room temperature. The solutions having different pH's were tested at day 0, 1, 3, and 7 to measure the contents of ketorolac tromethamine by HPLC.
The results showed that ketorolac tromethamine (30 mg/ml) was stable for 7 days at room temperature at pH 5-9; the contents of ketorolac tromethamine were 98.4-101.7% after 7 days. b. Stability of Tramadol
Tramadol (50 mg/ml, pH 6-8) was obtained from Grunenthal GMBH Products. The tramadol solutions were adjusted to different pH (pH 5, 6, 7, 8, and 9) with HCl or NaOH and stored at room temperature. The solutions having different pH's were tested at day 0, 1, 3, and 7 to measure the contents of tramadol by HPLC. The results showed that tramadol was stable for 7 days at room temperature at pH 5-8; the contents of tramadol were 97.4-102.4% after 7 days. At pH 9, tramadol precipitated out and had 70.4% of the initial amount remained in the solution at day 0, and had 56.4% of the initial amount remained in the solution after day 1, 3, 7, days. c. Stability of Ketorolac and Tramadol
Ketorolac tromethamine (30 mg/ml) and tramadol (50 mg/ml) were mixed together with saline to provide a mixture solution containing ketorolac tromethamine (2 mg/ml) and Tramadol (20 mg/ml). The mixture solutions were adjusted to different pH (pH 5, 6, 7, 8, and 9) with HC1 or NaOH and stored at room temperature. The mixture solutions were observed for its appearance at day 0, 1, 3, and 7.
At pH 5.0 and 6.0, the mixture solutions were clear but having little suspended solids at day 0, with no significant changes at day 1, 3, and 7. At pH 7.0 and 8.0, the mixture solutions were clear at day 0-7. At pH 9, turbulent precipitation was observed immediately at day 0, and needle-like crystals were seen from day 1-7.
The results showed that the mixture solution was stable for 7 days at room
temperature at pH 5-8, but was not stable at pH 9.
Example 2. Use of Ketorolac and Tramadol for Post-Operative Pain
Objectives
The objective of this study is to test the safety profiles and efficacy for pre-mixed ketorolac and tramadol liquid formulation for treatment of post-operative pain.
Subjects
A total of 63 subjects were randomized in this study. Most subjects (>90%) underwent an elective major abdominal surgery or gynecologic surgery (including laparoscopic surgery). Other subjects (<10%) underwent mastectomy.
Drug Dosage
Ketorolac tromethamine (Keto, 30 mg/ml) was obtained from Yung Shin
Pharmaceuticals Ind. Co., Ltd. Tramadol hydrochloride (50 mg/ml) was obtained from Grunenthal GMBH Products. The two drugs were pre-mixed together with saline to a total volume of 12.0 or 12.5 ml to provide 5 different concentrations as follows.
Group 1. Keto 6 mg/ml only (maximum dose 60 mg in 10 ml), n=12 Group 2. Keto 6 mg/ml, tramadol 4 mg/ml (maximum doses 60 mg keto and 40 mg tramadol in 10 ml), n=13
Group 3. Keto 4.5 mg/ml, tramadol 7.5 mg/ml (maximum doses 45 mg keto and 75 mg tramadol in 10 ml), n=13
Group 4. Keto 3 mg/ml, tramadol 10 mg/ml (maximum doses 30 mg keto and 100 mg tramadol in 10 ml), n=12
Group 5. Tramadol 10 mg/ml only (maximum doses 100 mg tramadol in 10 ml), n=13
The initial dose (quarter of the maximum dose) of 2.5 ml was given by intravenous injection to each patient at time zero, and then doses of 2.5 ml were given by intravenous injection to the patient every 10 minutes, until the patient's pain score was < 5 or the dose is used up. Study Protocols
After awaking from surgery, subjects rated their most severe pain score > 5 were randomized to one of the five groups of ketorolac and/or tramadol. An initial dose of a quarter of volume (2.5 ml) treatment was given to patients, and subsequently 2.5 ml was given at about 10 minutes, 20 minutes, and 30 minutes, if subject's most severe pain level was still moderate to severe (pain score > 5). The pain scores and vital signs were assessed every 5 minutes after each dose. If the subject rated the most severe pain score < 5 or the subject had received the maximum dose, then the subject stopped taking the liquid ketorolac and tramadol formulation and the subject was given direct access to a morphine PCA pump.
Visual Analog Scale (VAS) scoring system was used to assess the pain intensity (0- 10) by patient. 10 means the most severe pain and 0 means no pain. A horizontal line, 10 cm (100 mm) in length, was anchored by word descriptors, "No pain" and "Very severe pain", at each end. The VAS score was determined by measuring in millimeters from the left hand end of the line to the point that the subject marks. The study nurse measured the length from point 0 (no pain) to the mark and transcript to a number between 0.0 to 10.0 cm. The pain score at 0, 5, 10, 15, 20, 35, 30, 35, and 40 minutes of each patient were recorded.
Analysis of Results
All tests are based on two-sided alternative hypotheses and were made at 5% significance level. For the efficacy endpoints, the Van Der Waerden test was conducted for accumulative total unit dose of combination ketorolac and tramadol.
(en.wikipedia.org/wiki/Van_der_Waerden_test) In addition, the correlation between combinative rate (ketorolac dose: tramadol dose) and accumulative total unit dose for combination of ketorolac and tramadol for pain relief are modeled by regression method, if appropriate.
Fisher exact test was used to compare treatment groups for the proportion of subjects with a score of less than 5. (en.wikipedia.org/wiki/Fisher's_exact_test)
For the safety variables, summary frequency tables for adverse events were provided by the treatment group. Descriptive statistics were used for vital signs data.
Results and Conclusions
The mean VAS score of each group at 0, 5, 10, 15, 20, 35, 30, 35, and 40 minutes was plotted vs. time from the initial injection and shown as FIG. 1.
As shown in FIG. 1, patients treated with Group I (Keto only), III (maximum doses 45 mg keto and 75 mg tramadol in 10 ml), and V (Tramadol only) did not reduce their pain scores reduced to less than 6.
In contrast, patients treated with Group II (maximum doses 60 mg keto and 40 mg tramadol in 10 ml) reduced pain score to < 5 at about 28-35 minutes, or 30-35 minutes. The accumulated dosages at 28-35 minutes are calculated to be ketorolac, 42-52.5 mg, and tramadol, 28-35 mg. The accumulated dosages at 30-35 minutes are calculated to be ketorolac, 45-52.5 mg, and tramadol, 30-35 mg.
In addition, patients treated with Group IV (maximum doses 30 mg keto and 100 mg tramadol in 10 ml) reduced pain score to < 5.3 at about 25-35 minutes, or 28-35 minutes, and the pain score was even lower at 40 minutes. In considering the adverse effect of high dosage of tramadol, a lower dosage of tramadol for reaching pain score < 5.3 is preferred.
The accumulated dosages at 25-35 minutes are calculated to be ketorolac, 18.75-26.25 mg, and tramadol, 62.5-87.5 mg. The accumulated dosages at 28-35 minutes are calculated to be ketorolac, 21-26.25 mg, and tramadol, 70-87.5 mg.

Claims

WHAT IS CLAIMED IS:
1. A liquid pharmaceutical composition for treating a patient having moderate to severe pain, comprising an effective amount of ketorolac or ketorolac tromethamine, and an effective amount of tramadol or its pharmaceutically acceptable salt, in an aqueous formulation,
wherein the effective amount of ketorolac or ketorolac tromethamine is 42-52.5 mg, and the effective amount of tramadol or its pharmaceutically acceptable salt is 28-35 mg.
2. The liquid pharmaceutical composition according to Claim 1, wherein the effective amount of ketorolac or ketorolac tromethamine is 45-52.5 mg, and the effective amount of tramadol or its pharmaceutically acceptable salt is 30-35 mg.
3. A liquid pharmaceutical composition for treating a patient having moderate to severe pain, comprising an effective amount of ketorolac or ketorolac tromethamine, and an effective amount of tramadol or its pharmaceutically acceptable salt, in an aqueous formulation,
wherein the effective amount of ketorolac or ketorolac tromethamine is 18.75-26.25 mg, and the effective amount of tramadol or its pharmaceutically acceptable salt is 62.5-87.5 mg.
4. The liquid pharmaceutical composition according to Claim 3, wherein the effective amount of ketorolac or ketorolac tromethamine is 21-26.25 mg, and the effective amount of tramadol or its pharmaceutically acceptable salt is 70-87.5 mg.
5. The liquid pharmaceutical composition according to Claim 1 or 3, wherein the patient has pain intensity of 6-9.
6. The liquid pharmaceutical composition according to Claim 1 or 3, wherein the patient has pain intensity of 8-9.
7. The liquid pharmaceutical composition according to Claim 6, for reducing the pain score of the patient from 8-9 to 5.3 or less.
8. The liquid pharmaceutical composition according to Claim 1 or 3, wherein the composition is in a solution form, a suspension form, or an emulsion form.
9. The liquid pharmaceutical composition according to Claim 1 or 3, which has a pH of 5-8.
10. The liquid pharmaceutical composition according to Claim 1 or 3, wherein the pain is post-operative pain, cancer pain, visceral pain, or trauma pain.
1 1. The liquid pharmaceutical composition according to Claim 1 or 3, which is administered by intravenous injection.
12. The liquid pharmaceutical composition according to Claim 1 or 3, which is administered by intramuscular injection.
PCT/US2013/037737 2012-04-25 2013-04-23 Liquid pharmaceutical formulation containing ketorolac and tramadol WO2013163142A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261638431P 2012-04-25 2012-04-25
US61/638,431 2012-04-25

Publications (1)

Publication Number Publication Date
WO2013163142A1 true WO2013163142A1 (en) 2013-10-31

Family

ID=49483817

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/037737 WO2013163142A1 (en) 2012-04-25 2013-04-23 Liquid pharmaceutical formulation containing ketorolac and tramadol

Country Status (2)

Country Link
TW (1) TW201347784A (en)
WO (1) WO2013163142A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015166418A3 (en) * 2014-04-29 2016-01-07 Laboratorios Liomont, S.A. De C.V. Pharmaceutical composition for the treatment of allopathic pain, using ketorolac tromethamine and tramadol hydrochloride as an active ingredient
WO2019122982A1 (en) 2017-12-21 2019-06-27 Grünenthal GmbH Pharmaceutical combination in a bilayer tablet form comprising ketorolac tromethamine and tramadol hydrochloride, and its use in pain treatment
WO2019143234A1 (en) * 2018-01-22 2019-07-25 AMÉZCUA AMÉZCUA, Federico Synergistic pharmaceutical combination of the active enantiomer s-ketorolac tromethamine and tramadol chlorhydrate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087644A1 (en) * 2002-11-04 2004-05-06 Leopoldo Espinosa Abdala Pharmaceutical composition in capsules that comprises a non-steroidal antiinflamatory and an optiate analgesic for handling pain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087644A1 (en) * 2002-11-04 2004-05-06 Leopoldo Espinosa Abdala Pharmaceutical composition in capsules that comprises a non-steroidal antiinflamatory and an optiate analgesic for handling pain

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DE FRANCESCHI, L. ET AL.: "A pilot study on the efficacy of ketorolac plus tramadol infusion combined with erythrocytapheresis in the management of acute severe vaso-occlusive crises and sickle cell pain", HAEMATOLOGICA, vol. 89, no. 11, 2004, pages 1389 - 1391 *
LIN, T.-F. ET AL.: "Compatibility and stability of binary mixtures of ketorolac tromethamine and tramadol hydrochloride injection concentrate and diluted infusion solution", ACTA ANAESTHESIOLOGICA TAIWANICA, vol. 48, no. 3, 2010, pages 117 - 121 *
LOPEZ-MUNOZ, F. J. ET AL.: "Analysis of the analgesic interactions between ketorolac and tramadol during arthritic nociception in rat", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 484, 2004, pages 157 - 165 *
POMPEO, E. ET AL.: "The role of awake video-assisted thoracoscopic surgery in spontaneous pneumothorax", THE JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, vol. 133, no. 3, 2007, pages 786 - 790 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015166418A3 (en) * 2014-04-29 2016-01-07 Laboratorios Liomont, S.A. De C.V. Pharmaceutical composition for the treatment of allopathic pain, using ketorolac tromethamine and tramadol hydrochloride as an active ingredient
WO2019122982A1 (en) 2017-12-21 2019-06-27 Grünenthal GmbH Pharmaceutical combination in a bilayer tablet form comprising ketorolac tromethamine and tramadol hydrochloride, and its use in pain treatment
WO2019143234A1 (en) * 2018-01-22 2019-07-25 AMÉZCUA AMÉZCUA, Federico Synergistic pharmaceutical combination of the active enantiomer s-ketorolac tromethamine and tramadol chlorhydrate

Also Published As

Publication number Publication date
TW201347784A (en) 2013-12-01

Similar Documents

Publication Publication Date Title
Seki et al. Postoperative pain management in patients undergoing posterior spinal fusion for adolescent idiopathic scoliosis: a narrative review
Camu et al. Pharmacology of systemic analgesics
Swenson et al. Intravenous lidocaine is as effective as epidural bupivacaine in reducing ileus duration, hospital stay, and pain after open colon resection: a randomized clinical trial
CA2569072C (en) Preparation for localized delivery of therapeutic agent
Siu et al. Opioid-free and opioid-sparing anesthesia
Helander et al. Multimodal approaches to analgesia in enhanced recovery after surgery pathways
Rana et al. Perioperative pain control in the ambulatory setting
US20040209850A1 (en) Methods of treating pain and compositions for use therefor
Tiippana et al. Effect of paracetamol and coxib with or without dexamethasone after laparoscopic cholecystectomy
Candido et al. Pharmacology of acetaminophen, nonsteroidal antiinflammatory drugs, and steroid medications: implications for anesthesia or unique associated risks
Yu et al. The development of local anesthetics and their applications beyond anesthesia
JP2011506505A (en) Medicament and its production method and use in the treatment of painful neuropathy
WO2013163142A1 (en) Liquid pharmaceutical formulation containing ketorolac and tramadol
CA2476939A1 (en) Pharmaceutical combinations of cox-2 inhibitors and opiates
Kutlu Yalcin et al. Emerging drugs for the treatment of postsurgical pain
US5616618A (en) Threo-3-(3,4-dihydroxyphenyl)serine analgesic composition
KR20100047860A (en) Treatment of neuropathic pain
Young et al. Multimodal systemic and intra-articular analgesics
CN109758452A (en) Medicinal use of amine compounds in the treatment of pain
Toscano et al. Multimodal opioid sparing
Buvanendran Multimodal analgesia for perioperative pain management
Talebi et al. Perioperative pain: molecular mechanisms and future perspectives
JP2002541203A (en) Pain management after joint surgery
US12070454B1 (en) Anesthetic nerve block and method
US11890422B2 (en) Anesthetic nerve block and method

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13782025

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13782025

Country of ref document: EP

Kind code of ref document: A1